{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-078665","form_type":"8-K","ticker":"TVRD","cik":"0001346830","company_name":"Tvardi Therapeutics, Inc.","filed_at":"2025-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.790325+00:00","generated_at":"2026-05-17T12:57:56.052145+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Tvardi Therapeutics Q2 net income $4.2M; IPF Phase 2 topline data on track for Q4 2025","bullets":["Net income of $4.2M vs. net loss of $7.0M in Q2 2024; driven by $12.8M remeasurement gain on convertible notes.","Basic EPS of $0.51; diluted EPS loss of $1.00.","R&D expenses $5.8M (down $0.7M YoY); G&A expenses $3.1M (up $2.4M due to merger costs).","Cash, equivalents, and short-term investments $41.0M as of June 30, 2025; runway into Q4 2026.","REVERT IPF Phase 2 trial fully enrolled; topline data expected Q4 2025. IND for TTI-109 submitted to FDA in June 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-078665","json":"https://secwatch.observer/filing/0001104659-25-078665.json","markdown":"https://secwatch.observer/filing/0001104659-25-078665.md","text":"https://secwatch.observer/filing/0001104659-25-078665.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925078665/0001104659-25-078665-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1346830/000110465925078665/tm2523431d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T12:57:56.052145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}